Research Article

Fenilketonüri: Olgu Sunumu

Volume: 2 Number: 2 October 10, 2016

Fenilketonüri: Olgu Sunumu

Abstract

Fenilketonüri (FKU), fenilalanin hidroksilaz enziminin eksikliği ile

görülen otozomal resesif geçişli yenidoğan metabolizma hastalğdr.

Hastalk, geç fark edildiği ya da tedavisi yaplmadğ zaman hastay mental

retardasyona kadar götüren bir seyire sahiptir. Fenilketonürinin kesin

tedavisi yoktur. Hastalara hayat boyu tedavi verilir: bu tedaviler, BH4

tedavisi(eğer yantl ise) ve ya fenilalaninden kstl diyet tedavisidir. Bu

makalede İstanbul Cerrahpaşa Tp Fakültesi Çocuk Hastalklar

Metabolizma Bölümü’ne getirilen yenidoğan taramasnda fenilalanin

yüksekliği tespit edilen 16 günlük kz bebeğe uygulanan tedavi protokolü

anlatlmştr.

Keywords

References

  1. [1] Zurfluh, M. R., Zschocke, J., Lindner, M., Feillet, F., Chery, C., Burlina, A., Stevens, R. C., Thony, B., Blau, N. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum. Mutat. 29: 167-175, 2008. Note: Erratum: Hum. Mutat. 29: 1079 only, 2008. [2] Aktuğlu Zeybek, Ç. Fenilketonüri tarama program. Sağlam Çocuk İzlemi Sempozyum Dizisi 2003 Ekim: (35); 65-71 [3] Brown, Christine S., and Uta Lichter-Konecki. "Phenylketonuria (PKU): A problem solved?." Molecular genetics and metabolism reports 6 (2016): 8-12. [4] Cleary, Maureen Anne. "Phenylketonuria." Paediatrics and Child Health 25.3 (2015): 108-112. [5] Aguado, C., Pérez, B., García, M. J., Bélanger-Quintana, A., Martínez-Pardo, M., Ugarte, M., & Desviat, L. R. (2007). BH4 responsiveness associated to a PKU mutation with decreased binding affinity for the cofactor. Clinica chimica acta, 380(1), 8- 12. [6] Vernon HJ, Koerner CB, Johnson MR, Bergner A, Hamosh A. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria. Mol Genet Metab. 2010 Jul. 100(3):229-33. [7] Anjema, K., van Rijn, M., Hofstede, F.C. et al. Orphanet J Rare Dis (2013) 8: 103. doi:10.1186/1750-1172-8-103) [8] Bosch AM, Tybout W, van Spronsen FJ, de Valk HW, Wijburg FA, Grootenhuis MA. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis. 2007 Feb. 30(1):29-34. [9] Brumm VL, Bilder D, Waisbren SE.. Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 2010;99:S59- S63. [10] Simon E, Schwarz M, Roos J, et al. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes2008;6:25.

Details

Primary Language

Turkish

Subjects

-

Journal Section

Research Article

Authors

Merve Pehlivan * This is me
Türkiye

Publication Date

October 10, 2016

Submission Date

July 22, 2016

Acceptance Date

-

Published in Issue

Year 2016 Volume: 2 Number: 2

APA
Pehlivan, M., & Kalkan, İ. (2016). Fenilketonüri: Olgu Sunumu. Aydın Sağlık Dergisi, 2(2), 57-62. https://izlik.org/JA52PG56TA
AMA
1.Pehlivan M, Kalkan İ. Fenilketonüri: Olgu Sunumu. Aydın Health. 2016;2(2):57-62. https://izlik.org/JA52PG56TA
Chicago
Pehlivan, Merve, and İndrani Kalkan. 2016. “Fenilketonüri: Olgu Sunumu”. Aydın Sağlık Dergisi 2 (2): 57-62. https://izlik.org/JA52PG56TA.
EndNote
Pehlivan M, Kalkan İ (October 1, 2016) Fenilketonüri: Olgu Sunumu. Aydın Sağlık Dergisi 2 2 57–62.
IEEE
[1]M. Pehlivan and İ. Kalkan, “Fenilketonüri: Olgu Sunumu”, Aydın Health, vol. 2, no. 2, pp. 57–62, Oct. 2016, [Online]. Available: https://izlik.org/JA52PG56TA
ISNAD
Pehlivan, Merve - Kalkan, İndrani. “Fenilketonüri: Olgu Sunumu”. Aydın Sağlık Dergisi 2/2 (October 1, 2016): 57-62. https://izlik.org/JA52PG56TA.
JAMA
1.Pehlivan M, Kalkan İ. Fenilketonüri: Olgu Sunumu. Aydın Health. 2016;2:57–62.
MLA
Pehlivan, Merve, and İndrani Kalkan. “Fenilketonüri: Olgu Sunumu”. Aydın Sağlık Dergisi, vol. 2, no. 2, Oct. 2016, pp. 57-62, https://izlik.org/JA52PG56TA.
Vancouver
1.Merve Pehlivan, İndrani Kalkan. Fenilketonüri: Olgu Sunumu. Aydın Health [Internet]. 2016 Oct. 1;2(2):57-62. Available from: https://izlik.org/JA52PG56TA

All site content, except where otherwise noted, is licensed under a Creative Common Attribution Licence. (CC-BY-NC 4.0)